These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 29118324)

  • 21. Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells.
    Parsels LA; Morgan MA; Tanska DM; Parsels JD; Palmer BD; Booth RJ; Denny WA; Canman CE; Kraker AJ; Lawrence TS; Maybaum J
    Mol Cancer Ther; 2009 Jan; 8(1):45-54. PubMed ID: 19139112
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma.
    Liu Y; Li Y; Wang X; Liu F; Gao P; Quinn MM; Li F; Merlino AA; Benes C; Liu Q; Gray NS; Wong KK
    Cancer Res; 2017 Sep; 77(18):5068-5076. PubMed ID: 28754670
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ataxia telangiectasia and Rad3-related inhibition by AZD6738 enhances gemcitabine-induced cytotoxic effects in bladder cancer cells.
    Isono M; Okubo K; Asano T; Sato A
    PLoS One; 2022; 17(4):e0266476. PubMed ID: 35413091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells.
    Zemanova J; Hylse O; Collakova J; Vesely P; Oltova A; Borsky M; Zaprazna K; Kasparkova M; Janovska P; Verner J; Kohoutek J; Dzimkova M; Bryja V; Jaskova Z; Brychtova Y; Paruch K; Trbusek M
    Oncotarget; 2016 Sep; 7(38):62091-62106. PubMed ID: 27556692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma.
    Al-Ejeh F; Pajic M; Shi W; Kalimutho M; Miranda M; Nagrial AM; Chou A; Biankin AV; Grimmond SM; ; Brown MP; Khanna KK
    Clin Cancer Res; 2014 Jun; 20(12):3187-97. PubMed ID: 24838526
    [TBL] [Abstract][Full Text] [Related]  

  • 26. mTORC1/2 and Protein Translation Regulate Levels of CHK1 and the Sensitivity to CHK1 Inhibitors in Ewing Sarcoma Cells.
    Koppenhafer SL; Goss KL; Terry WW; Gordon DJ
    Mol Cancer Ther; 2018 Dec; 17(12):2676-2688. PubMed ID: 30282812
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A kinome screen identifies checkpoint kinase 1 (CHK1) as a sensitizer for RRM1-dependent gemcitabine efficacy.
    Zhou J; Chen Z; Malysa A; Li X; Oliveira P; Zhang Y; Bepler G
    PLoS One; 2013; 8(3):e58091. PubMed ID: 23483975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Co-Inhibition of the DNA Damage Response and CHK1 Enhances Apoptosis of Neuroblastoma Cells.
    Ando K; Nakamura Y; Nagase H; Nakagawara A; Koshinaga T; Wada S; Makishima M
    Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31362335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo.
    Montano R; Thompson R; Chung I; Hou H; Khan N; Eastman A
    BMC Cancer; 2013 Dec; 13():604. PubMed ID: 24359526
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CHK1 inhibition as a strategy for targeting Fanconi Anemia (FA) DNA repair pathway deficient tumors.
    Chen CC; Kennedy RD; Sidi S; Look AT; D'Andrea A
    Mol Cancer; 2009 Apr; 8():24. PubMed ID: 19371427
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RNA interferences targeting the Fanconi anemia/BRCA pathway upstream genes reverse cisplatin resistance in drug-resistant lung cancer cells.
    Dai CH; Li J; Chen P; Jiang HG; Wu M; Chen YC
    J Biomed Sci; 2015 Sep; 22(1):77. PubMed ID: 26385482
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents.
    Chen CC; Taniguchi T; D'Andrea A
    J Mol Med (Berl); 2007 May; 85(5):497-509. PubMed ID: 17221219
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading.
    Hauge S; Naucke C; Hasvold G; Joel M; Rødland GE; Juzenas P; Stokke T; Syljuåsen RG
    Oncotarget; 2017 Feb; 8(7):10966-10979. PubMed ID: 28030798
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target.
    Liu Y; Kwiatkowski DJ
    Mol Cancer Ther; 2015 Jan; 14(1):174-82. PubMed ID: 25349305
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival.
    Karnitz LM; Flatten KS; Wagner JM; Loegering D; Hackbarth JS; Arlander SJ; Vroman BT; Thomas MB; Baek YU; Hopkins KM; Lieberman HB; Chen J; Cliby WA; Kaufmann SH
    Mol Pharmacol; 2005 Dec; 68(6):1636-44. PubMed ID: 16126823
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rad18 E3 ubiquitin ligase activity mediates Fanconi anemia pathway activation and cell survival following DNA Topoisomerase 1 inhibition.
    Palle K; Vaziri C
    Cell Cycle; 2011 May; 10(10):1625-38. PubMed ID: 21478670
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fanconi anemia pathway heterogeneity revealed by cisplatin and oxaliplatin treatments.
    Kachnic LA; Li L; Fournier L; Willers H
    Cancer Lett; 2010 Jun; 292(1):73-9. PubMed ID: 20034732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.
    Walton MI; Eve PD; Hayes A; Henley AT; Valenti MR; De Haven Brandon AK; Box G; Boxall KJ; Tall M; Swales K; Matthews TP; McHardy T; Lainchbury M; Osborne J; Hunter JE; Perkins ND; Aherne GW; Reader JC; Raynaud FI; Eccles SA; Collins I; Garrett MD
    Oncotarget; 2016 Jan; 7(3):2329-42. PubMed ID: 26295308
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Chk1 inhibitor MK-8776 increases the radiosensitivity of human triple-negative breast cancer by inhibiting autophagy.
    Zhou ZR; Yang ZZ; Wang SJ; Zhang L; Luo JR; Feng Y; Yu XL; Chen XX; Guo XM
    Acta Pharmacol Sin; 2017 Apr; 38(4):513-523. PubMed ID: 28042876
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1.
    Blasina A; Hallin J; Chen E; Arango ME; Kraynov E; Register J; Grant S; Ninkovic S; Chen P; Nichols T; O'Connor P; Anderes K
    Mol Cancer Ther; 2008 Aug; 7(8):2394-404. PubMed ID: 18723486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.